Table 1 Baseline of demographic characteristics and laboratory data
| Characteristic |
All patients (n = 134) |
Continuation group (n = 81) |
Non-continuation group (n = 53) | p value |
|---|---|---|---|---|
| Age (y) | 82 (76–85) | 80 (73–84) | 83 (80.5–88) | 0.0013† |
| Gender n, (%) | 0.4166§ | |||
| Male | 50 (37.3) | 28 (34.6) | 22 (41.5) | |
| Female | 84 (62.7) | 53 (65.4) | 31 (58.5) | |
| Length of stay (d) | 42 (29–55.8) | 40 (28.5–58.5) | 45 (29–54) | 0.5571† |
| Body weight at admission (kg) | 50 (44–60) | 51 (43.1–63.9) | 48.2 (42–56.8) | 0.0502† |
| BMI at admission (kg/m2) | 21.4 (18.8–24.1) | 22.1 (19.2–25.1) | 20.7 (17.8–23.2) | 0.0115† |
| Primary diagnosis n, (%) | 0.6419§ | |||
| Cerebral infraction | 10 (7.5) | 6 (7.4) | 4 (7.6) | |
| Intracerebral hemorrhage | 7 (5.2) | 3 (3.7) | 4 (7.6) | |
| Subarachnoid hemorrhage | 2 (1.5) | 2 (2.5) | 0 (0) | |
| Osteoporosis–related disease | 104 (77.6) | 64 (79.0) | 40 (75.4) | |
| Hospital-associated deconditioning | 1 (0.7) | 1 (1.2) | 0 (0) | |
| Others | 10 (7.5) | 5 (6.2) | 5 (9.4) | |
| Comorbid conditions n, (%) | ||||
| Cardiac disease | 18 (13.3) | 11 (13.6) | 7 (13.2) | 0.9507§ |
| Diabetes mellitus | 30 (22.2) | 15 (18.5) | 15 (28.3) | 0.1840§ |
| Hypertension | 87 (64.4) | 58 (71.6) | 29 (54.7) | 0.0452§ |
| Dyslipidemia | 40 (29.6) | 31 (38.3) | 9 (17) | 0.0085§ |
| Dementia | 2 (1.5) | 0 (0) | 2 (3.8) | 0.0782§ |
| Epilepsy | 3 (2.2) | 1 (1.2) | 2 (3.8) | 0.3313§ |
| Parkinson’s disease | 2 (1.5) | 1 (1.2) | 1 (1.9) | 0.7608§ |
| Family cooperation n, (%) | 117 (87.3) | 72 (88.9) | 45 (84.9) | 0.4981§ |
| HDS-R | 25 (21–28) | 26 (23–28) | 23 (19–26) | 0.0011§ |
| Upper limb paralysis n, (%) | 22 (16.3) | 12 (14.8) | 10 (18.9) | 0.5357§ |
| Higher brain dysfunction n, (%) | 24 (17.9) | 9 (11.1) | 15 (28.3) | |
| Vision loss n, (%) | 14 (10.4) | 9 (11.1) | 5 (9.4) | 0.7563§ |
| No. of medications at admission | 6.7 ± 3.5 | 6.8 ± 3.2 | 6.8 ± 3.8 | 0.8388§ |
| medication instruction n, (%) | 134 (100) | 81 (100) | 53 (100) | 0.2146§ |
| No. of medication instructions | 6 (4–9) | 7 (5–10) | 5 (2.5–7) | <.0001† |
| FIM at admission (points) | ||||
| FIM–M | 50 (33–60) | 52 (37.5–59) | 46 (29.5–63.6) | 0.1497† |
| FIM–C | 30 (26–35) | 32 (29–35) | 28 (21.5–33) | 0.0011† |
| FIM–T | 79 (63–92) | 82 (69.5–93) | 73 (57.5–91.5) | 0.0166† |
| FIM at discharge (points) | ||||
| FIM–M | 82 (74–86) | 83 (76.5–86) | 78 (67–85) | 0.0084† |
| FIM–C | 34 (30–35) | 35 (32–35) | 30 (26–34.5) | <.0001† |
| FIM–T | 114 (103.5–119.5) | 117 (108.3–121) | 109 (93.5–115.5) | 0.0004† |
| Clinical laboratory data at admission | ||||
| Alb (g/dL) | 3.4 ± 0 .6 | 3.5 ± 0.5 | 3.2 ± 0.7 | 0.0097‡ |
| CRP (mg/dL) | 0.46 (0.19–1.30) | 0.41 (0.11–1.15) | 0.68 (0.27–1.39) | 0.2354† |